These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 23582367)

  • 1. Three molecular classifications surrogate to four immunohistochemical markers in 374 invasive breast carcinomas with long follow-up: which is better?
    Ruiz Martín J; Pérez Sánchez C; de las Heras Camino A
    Pathol Res Pract; 2013 Jun; 209(6):337-44. PubMed ID: 23582367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of estrogen receptor, progesterone receptor, HER2/neu, Ki-67, and nm23 expression in patients with invasive breast cancer.
    Cubukcu E; Kanat O; Fatih Olmez O; Kabul S; Canhoroz M; Avci N; Deligonul A; Hartavi M; Cubukcu S; Olmez F; Kurt E; Evrensel T; Gokgoz S; Manavoglu O
    J BUON; 2013; 18(2):359-65. PubMed ID: 23818346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma.
    Liu F; Cui L; Zhang Y; Chen L; Wang Y; Fan Y; Lei T; Gu F; Lang R; Pringle GA; Zhang X; Chen Z; Fu L
    Breast Cancer Res Treat; 2010 Dec; 124(3):677-88. PubMed ID: 20213083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of Rsf-1 correlates with pathological type, p53 status and survival in primary breast cancer.
    Ren J; Chen QC; Jin F; Wu HZ; He M; Zhao L; Yu ZJ; Yao WF; Mi XY; Wang EH; Wei MJ
    Int J Clin Exp Pathol; 2014; 7(9):5595-608. PubMed ID: 25337201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy.
    Ladoire S; Arnould L; Mignot G; Coudert B; Rébé C; Chalmin F; Vincent J; Bruchard M; Chauffert B; Martin F; Fumoleau P; Ghiringhelli F
    Breast Cancer Res Treat; 2011 Jan; 125(1):65-72. PubMed ID: 20229175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
    Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
    Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
    Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 status in unusual histological variants of gastric adenocarcinomas.
    Giuffrè G; Ieni A; Barresi V; Caruso RA; Tuccari G
    J Clin Pathol; 2012 Mar; 65(3):237-41. PubMed ID: 22067088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of Abl interactor 1 and its prognostic significance in breast cancer: a tissue-array-based investigation.
    Wang C; Tran-Thanh D; Moreno JC; Cawthorn TR; Jacks LM; Wang DY; McCready DR; Done SJ
    Breast Cancer Res Treat; 2011 Sep; 129(2):373-86. PubMed ID: 21046228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p-mTOR expression is associated with better prognosis in luminal breast carcinoma.
    Beca F; Andre R; Martins DS; Bilhim T; Martins D; Schmitt F
    J Clin Pathol; 2014 Nov; 67(11):961-7. PubMed ID: 25053543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
    Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
    Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
    Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
    J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of HER 2/neu gene amplification with immunohistochemistry and other prognostic factors in breast carcinoma.
    Ramadan SS; Yapicier O; Kıhtır S; Erdemır A; Doğan TH; Uskent I; Onat H; Cakmakçi M
    Turk Patoloji Derg; 2011; 27(3):196-203. PubMed ID: 21935868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
    Petit T; Wilt M; Velten M; Rodier JF; Fricker JP; Dufour P; Ghnassia JP
    Breast Cancer Res Treat; 2010 Nov; 124(2):387-91. PubMed ID: 20824324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone receptor expression in invasive breast cancer among Korean women and comparison of 3 antiestrogen receptor antibodies: a multi-institutional retrospective study using tissue microarrays.
    Bae YK; Gong G; Kang J; Lee A; Cho EY; Lee JS; Suh KS; Lee DW
    Am J Surg Pathol; 2012 Dec; 36(12):1817-25. PubMed ID: 23154769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
    Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
    Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
    Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
    Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis.
    Aleskandarany MA; Rakha EA; Ahmed MA; Powe DG; Paish EC; Macmillan RD; Ellis IO; Green AR
    Breast Cancer Res Treat; 2010 Jul; 122(1):45-53. PubMed ID: 19701705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
    Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
    Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.